Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

Universidad Carlos III de Madrid (UC3M) has presented three scientific research projects contributing to the fight against tuberculosis, the leading cause of death from infectious disease in the world ...

The stock market ended the first trading day of the week in the negative territory, with all major indices recording hefty ...

Autologous mononuclear cells showed substantial activity in patients with advanced heart failure — and even though the study ...

The global humanized mouse model market is poised for substantial growth, with projections indicating a rise from USD 101.5 million in 2023 to USD 178.3 million by 2033, growing at a steady CAGR of ...

Exicure, Inc. (Nasdaq: XCUR) today announced that GPCR Therapeutics USA, a subsidiary of Exicure Inc., has dosed the 19th patient in its ongoing Phase 2 clinical trial evaluating GPC-100 (burixafor), ...

CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction ...

In extensive testing, the ATB™ has demonstrated high cell densities and viabilities for primary T-cells and CD34+ stem cells, as well as HEK293 and CHO cell lines. “The ATB™ introduction is another ...